Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project.

Publikation

Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project.

Wissenschaftlicher Artikel/Review - 28.08.2024

Hilser Thomas, Darr Christopher, Niegisch Günter, Schnabel Marco Julius, Foller Susan, Häuser Lorine, Zschäbitz Stefanie, Lewerich Jonas, Ivanyi Philipp, Schlack Katrin, Paffenholz Pia, Daetwyler Eveline, Niedersüß-Beke Dora, Grünwald Viktor

Zitation

Hilser T, Darr C, Niegisch G, Schnabel M, Foller S, Häuser L, Zschäbitz S, Lewerich J, Ivanyi P, Schlack K, Paffenholz P, Daetwyler E, Niedersüß-Beke D, Grünwald V. Cabozantinib Plus Nivolumab in Adult Patients with Advanced or Metastatic Renal Cell Carcinoma: A Retrospective, Non-Interventional Study in a Real-World Cohort/GUARDIANS Project. Cancers (Basel) 2024; 16

Art

Wissenschaftlicher Artikel/Review (Englisch)

Zeitschrift

Cancers (Basel) 2024; 16

Veröffentlichungsdatum

28.08.2024

ISSN (Druck)

2072-6694

Kurzbeschreibung/Zielsetzung

Combinations of immune-checkpoint inhibitors (ICIs) are the standard of care (SOC) for treatment-naive metastatic renal cell carcinoma (mRCC) patients. In this multicenter study, we evaluated the RW safety and efficacy of cabozantinib plus nivolumab in mRCC patients.